AUTHORS
Jason Westin, MD, MS, FACP, FASCO, Vladan Vucinic, MD2, Patricia Young, MD3, Stefania Bramanti, MD4, Patrick Connor Johnson, MD5, Michael D. Jain, MD, PhD6, Giuseppe Gritti, MD, PhD7, Javier Briones, MD, PhD8, Koji Kato, MD, PhD9, Juan-Manuel Sancho, MD PhD10, Mi Kwon , MD, PhD11, Carlos Solano, MD, PhD12, Shaun Fleming, MBBS (Hons), PhD13, Saurabh Dahiya, MD, FACP14, Alejandro Martín García-Sancho, MD, PhD15, Pedro Marques Ramos, PhD16, David Demanse17, Salif Diallo, MSc18, David Pearson, PhD19, Aiesha Zia, MSc20, Aisha Masood, MD21, Pere Barba, MD, PhD22
AFFILIATIONS
1 M.D. Anderson Cancer Center, Houston, Texas, United States
2 University Hospital of Leipzig, Leipzig, Germany
3 David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, United States
4 IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy
5 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 ASST Papa Giovanni XXIII, Bergamo, Italy
8 Hospital Sant Pau, Barcelona, Spain
9 Kyushu University Hospital, Fukuoka, Japan
10 ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain
11 Hospital General Universitario Gregorio Marañón, Faculty of Medicine, Complutense University of Madrid (UCM), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
12 Hospital Clínico Universitario-INCLIVA, Valencia, Spain
13 The Alfred Hospital, Department of Haematology, Melbourne, VIC, Australia, and Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
14 Stanford University School of Medicine, Stanford, California, United States
15 Hospital Universitario de Salamanca, IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain
16 Novartis Pharma AG, Basel, Switzerland
17 Novartis Pharma AG, Basel, Switzerland
18 Novartis Pharma AG, Basel, Switzerland
19 Novartis BioMedical Research, Basel, Switzerland
20 Novartis Pharma AG, Basel, Switzerland
21 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
22 Hospital Universitari Vall d’Hebron, Barcelona, Spain
ABSTRACT
Introduction: Patients (pts) with first-line high-risk large B-cell lymphoma (1L HR LBCL) (ie, International Prognostic Index [IPI] score of 3-5 or double-hit LBCL [DHL]), or who do not achieve a complete response (CR) at interim response assessment, have a high risk of relapse and death. CAR-T cell therapy, approved in the relapsed/refractory setting, is a promising approach in 1L HR LBCL. Rapcabtagene autoleucel is an investigational CD19-directed CAR-T cell therapy that utilizes the T-Charge™ platform to preserve T-cell stemness by rapidly manufacturing the product (<2 days). Here we report an analysis of the phase 2 trial investigating the efficacy and safety of rapcabtagene autoleucel in pts with 1L HR LBCL (NCT03960840), detailing the now completed enrollment with longer follow-up, updated safety, and informative translational data.
Methods: Eligible pts had histologically confirmed LBCL with an IPI score of 3-5 and/or DHL, and a Deauville score (DS) on positron emission tomography of 4 or 5 with stable disease or partial response (PR) after 2 cycles of standard 1L therapy. After leukapheresis, a third cycle of 1L therapy was required as bridging following a protocol amendment. Pts received lymphodepletion followed by one infusion of rapcabtagene autoleucel (12.5 × 106 cells). The primary end point was complete response rate (CRR). Secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), adverse events (AEs), and cellular kinetics.
Results: As of January 9, 2026, 53 pts received rapcabtagene autoleucel (median follow-up 13 mo [range 7-29]). Median age was 59 y (range 26-76). Cell of origin was germinal center B cell (GCB) in 49% of pts and non-GCB in 42%. 49% of pts had an IPI score of 4-5 or DHL, and 51% had an IPI score of 3 without DHL. At screening after 2 cycles of 1L therapy, 64% of pts had a DS of 4, 36% had a DS of 5, and 91% of pts had PR.
Following rapcabtagene autoleucel infusion, the CRR was 77% (95% CI: 64-88) and the ORR was 91% (95% CI: 79-97). Median DOR was not reached (95% CI: 14-NE mo); 6- and 12-mo DOR was 85% and 77%, respectively. Among pts with a CR, 6- and 12-mo DOR was 92% and 86%, respectively. Median PFS was not reached (95% CI: 15-NE mo); 6- and 12-mo PFS was 80% and 71%, respectively. Median OS was not reached (95% CI: 20-NE mo); 6- and 12-mo OS was 100% and 97%, respectively.
All pts experienced ≥1 AE. Cytokine release syndrome (CRS) occurred in 49% of pts (n = 20 grade 1, n = 6 grade 2, no grade ≥3). Median time to CRS onset was 11 days (range 1-20), and median duration was 4 days (range 1-47; 95th percentile, 10 days). Immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 4 pts (8%; n = 3 grade 1-2, n = 1 grade 3). Median time to ICANS onset was 15 days (range 10-32). All cases resolved; median duration was 19 days (range 2-190). Immune effector cell–associated hemophagocytic lymphohistiocytosis-like syndrome was reported in 8% of pts, all grade 2 events. Infections occurred in 66% of pts (grade ≥3, 19%). Grade ≥3 infections were reported in 7/53 pts (13%) within 12 wk of infusion, 0 pts between 12 wk and 1 y, and 3/31 pts (10%) >1 y post infusion. In pts with grade 3 or 4 cytopenias within 1 mo of infusion, the estimated probability of resolution by mo 2 (defined as grade ≤2) was ≥90%. As of the data cutoff, 3 deaths had occurred: 1 due to disease progression and 2 due to AEs (pneumonia and respiratory failure), all unrelated to rapcabtagene autoleucel per investigator. Both deaths attributed to AEs occurred after new anti-lymphoma therapy off protocol.
Biomarker analyses of paired apheresis and cell products identified that T-cell differentiation and memory phenotypes were maintained from leukapheresis to the manufactured rapcabtagene autoleucel product, with preservation of the proportion of less-differentiated naive/stem-cell memory T cells among total viable CD3+ cells. Cellular kinetics showed robust in vivo expansion of rapcabtagene autoleucel by qPCR, with a median maximal concentration (Cmax) of 47,700 copies/µg DNA; median time of Cmax was 14 days. B-cell aplasia (BCA) was seen in all pts; at 12 mo, 58% of pts had ongoing BCA.
Conclusions: Rapcabtagene autoleucel (12.5 × 106 CAR+ cells) results in promising high CRRs, with durable efficacy and a manageable safety profile in pts with 1L HR LBCL. As the study is ongoing, data are subject to change.
DISCLOSURES
Jason Westin, MD, MS, FACP, FASCO: ADC Therapeutics - Research Funding; Janssen - Research Funding; Allogene Therapeutics - Research Funding; MorphoSys/Incyte Corporation - Research Funding; Nurix - Research Funding; Novartis - Research Funding; Kite/Gilead - Research Funding; Bristol-Myers Squibb - Research Funding; Janssen Scientific Affairs - Research Funding; AstraZeneca - Research Funding; Genentech/Roche - Research Funding; Janssen Scientific Affairs - Consultancy (Includes expert testimony); Lyell Immunopharma - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Chugai Pharma - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Juno - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); MorphoSys/Incyte Corporation - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene/Juno - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen Scientific Affairs - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)